New/JJ
immunosuppressive/JJ
drug/NN
PNU156804/NN
blocks/VBZ
IL-2-dependent/JJ
proliferation/NN
and/CC
NF-kappa/NN
B/NN
and/CC
AP-1/NN
activation/NN
./.

We/PRP
had/VBD
previously/RB
shown/VBN
that/IN
the/DT
drug/NN
undecylprodigiosin/NN
(/(
UP/NN
)/)
blocks/VBZ
human/JJ
lymphocyte/NN
proliferation/NN
in/FW
vitro/FW
./.
=====
We/PRP
have/VBP
now/RB
investigated/VBN
the/DT
mechanism/NN
of/IN
action/NN
of/IN
a/DT
new/JJ
analogue/NN
of/IN
UP/NN
,/,
PNU156804/NN
,/,
which/WDT
shows/VBZ
a/DT
more/RBR
favorable/JJ
activity/NN
profile/NN
than/IN
UP/NN
in/IN
mice/NNS
./.
=====
We/PRP
demonstrate/VBP
here/RB
that/IN
the/DT
biological/JJ
effect/NN
of/IN
PNU156804/NN
in/FW
vitro/FW
is/VBZ
indistinguishable/JJ
from/IN
UP/NN
:/:
PNU156804/NN
blocks/VBZ
human/JJ
T/NN
cell/NN
proliferation/NN
in/IN
mid-late/JJ
G1/NN
,/,
as/IN
determined/VBN
by/IN
cell/NN
cycle/NN
analysis/NN
,/,
expression/NN
of/IN
cyclins/NNS
,/,
and/CC
cyclin-dependent/JJ
kinases/NNS
and/CC
retinoblastoma/NN
phosphorylation/NN
./.
=====
In/IN
addition/NN
,/,
we/PRP
show/VBP
that/IN
PNU156804/NN
does/VBZ
not/RB
block/VB
significantly/RB
the/DT
induction/NN
of/IN
either/DT
IL-2/NN
or/CC
IL-2R/NN
alpha-/NN
and/CC
gamma-chains/NNS
but/CC
inhibits/VBZ
IL-2-dependent/JJ
T/NN
cell/NN
proliferation/NN
./.
=====
We/PRP
have/VBP
investigated/VBN
several/JJ
molecular/JJ
pathways/NNS
that/WDT
are/VBP
known/VBN
to/TO
be/VB
activated/VBN
by/IN
IL-2/NN
in/IN
T/NN
cells/NNS
./.
=====
We/PRP
show/VBP
that/IN
PNU156804/NN
does/VBZ
not/RB
inhibit/VB
c-myc/NN
and/CC
bcl-2/NN
mRNA/NN
induction/NN
./.
=====
On/IN
the/DT
other/JJ
hand/NN
,/,
PNU156804/NN
efficiently/RB
inhibits/VBZ
the/DT
activation/NN
of/IN
the/DT
NF-kappa/NN
B/NN
and/CC
AP-1/NN
transcription/NN
factors/NNS
./.
=====
PNU156804/NN
inhibition/NN
of/IN
NF-kappa/NN
B/NN
activation/NN
is/VBZ
due/JJ
to/TO
the/DT
inhibition/NN
of/IN
the/DT
degradation/NN
of/IN
I/NN
kappa/NN
B-alpha/NN
and/CC
I/NN
kappa/NN
B-beta/NN
./.
=====
PNU156804/NN
action/NN
is/VBZ
restricted/JJ
to/TO
some/DT
signaling/NN
pathways/NNS
;/:
it/PRP
does/VBZ
not/RB
affect/VB
NF-kappa/NN
B/NN
activation/NN
by/IN
PMA/NN
in/IN
T/NN
cells/NNS
but/CC
blocks/VBZ
that/DT
induced/VBN
by/IN
CD40/NN
cross-linking/NN
in/IN
B/NN
lymphocytes/NNS
./.
=====
We/PRP
conclude/VBP
that/IN
the/DT
prodigiosin/NN
family/NN
of/IN
immunosuppressants/NNS
is/VBZ
a/DT
new/JJ
family/NN
of/IN
molecules/NNS
that/WDT
show/VBP
a/DT
novel/JJ
target/NN
specificity/NN
clearly/RB
distinct/JJ
from/IN
that/DT
of/IN
other/JJ
immunosuppressive/JJ
drugs/NNS
such/JJ
as/IN
cyclosporin/NN
A/NN
,/,
FK506/NN
,/,
and/CC
rapamycin/NN
./.